ArticleJournal of cutaneous pathology2026
Bispecific Dual-Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients.
Niloofar Sina et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.